Biogen, Investors Reach Deal In Alzheimer's Drug Litigation
A class of investors has reached a deal with Biogen Inc. to avoid a trial and resolve a suit over statements executives made as they launched an Alzheimer's drug, according to...To view the full article, register now.
Already a subscriber? Click here to view full article